Loading insider details...
Beta
Latest Form 4 (Jul 22, 2026): Exercise/Conversion of 25,000 NAMS shares, $297.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 22, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 25,000 | $297.5K |
| Jun 24, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 25,000 | $272.5K |
| May 27, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 60,000 | $600.0K |
| Jan 29, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 39,816 | $434.0K |
| Jan 27, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 38,172 | $416.1K |
| Jan 7, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale | 2,647 | $88.0K |
| Dec 29, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 75,117 | $751.2K |
| Sep 10, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 150,000 | $1.50M |
| Sep 5, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale | 18,073 | $453.5K |
| Sep 4, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Exercise/Conversion | 18,073 | n/a |